Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2023 16:04 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
March 09, 2023 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
March 01, 2023 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
February 06, 2023 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 30, 2023 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 24, 2023 07:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 23, 2023 16:11 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 08, 2023 12:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line...
November 14, 2022 16:06 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 07, 2022 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right